Emerging Company Profile: Capitalizing on its proprietary platform technologies designed to develop high efficacy, disease-specific and low cost stem cell products, South Korea's SCM Lifescience aims to prove in clinical trials how its product candidates differ from existing stem cell therapies.
When CKD Pharm Vice Chairman BG Rhee left the pharma firm and became CEO of SCM Lifescience in May, people were curious to know what had drawn him to the stem cell therapy company.
"First of all, Korea has a relative strength in regenerative medicine. And SCM’s differentiated, specialized technology stood out among regenerative...
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
